Livzon Pharmaceutical Group has been identified as an investor by Elicio Therapeutics, which just completed a series B round that takes its total financing to $63m.
US-based immuno-oncology therapy developer Elicio Therapeutics closed a $33m series B round on Wednesday, naming pharmaceutical group Livzon among its investors.
The company said investment firm Clal Biotechnology Industries and life sciences-focused venture capital firm Efung Capital are also part of its investor base, without confirming their participation in the latest round.
Elicio is developing cancer immunotherapies aimed at the lymph node, utilising its propietary Amphiphile platform, which allows immunogens and cell-therapy activators to be accurately targeted and delivered.
The…